Clinical reviews about Overall Incidence of Adverse Effects in Amiodarone Treatment

Amiodarone is a effective agent for the treatment of many cardiac rhythm disturbances, ranging from paroxysmal atrial fibril lation to intractable ventricular tachyarrhythmias. However, amiodarone causes variable adverse effects from minor to life threatening. The aim of this study was to review general incidence of and associated factors with the adverse effects of amiodarone medication. Eight hundred seventy six patients who had taken amiodarone regularly over three months or who stopped medication due to any adverse effect between November 1996 and March 2005 at Keimyung University Dongsan medical center were included. Ninty six patients (11.0%) developed the amiodarone toxicity in any type. Among them, 60 patients showed hypothyroidism and held 62.5%. 10 patients showed pulmonary toxicity and held 10.4%, 20 patients and 20.8%, 6 patients and 6.3%. Patients with toxicity were older than patients without toxicity as 65.1±12.1 and 61.9±13.4 yr (p=0.026). Total dose and duration of amiodarone medication in the toxicity group were 1615.4±1414.6 gm and 734.9±677.1 days and 565.4±668.1 gm and 1249.7±1411.6 days in non-toxicity group respectively. The incidence of amiodarone induced toxicity was generally lower than established reports. If we had done regular protocol for checking up amiodarone adverse effects, we could detect amiodarone induced toxicity more exactly. It suggests that an incidence of amiodarone induced adverse effects can be lessened and the toxicity is prevented to some degree treating patients with amiodarone more carefully and performing a regular follow up protocol during medication.

[1]  L. Siddoway Amiodarone: guidelines for use and monitoring. , 2003, American family physician.

[2]  A. Neskovic,et al.  Single-day loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. , 2001, American heart journal.

[3]  S. Connolly Evidence-based analysis of amiodarone efficacy and safety. , 1999, Circulation.

[4]  P. Pollak,et al.  Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. , 1999, The American journal of cardiology.

[5]  T. Guarnieri,et al.  Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. , 1999, Journal of the American College of Cardiology.

[6]  A. Weetman,et al.  Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy , 1998, Heart.

[7]  S. Connolly,et al.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.

[8]  S. Gottlieb Dead is dead—artificial definitions are no substitute , 1997, The Lancet.

[9]  S. Hammill,et al.  Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences. , 1996, Heart.

[10]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[11]  J J Heger,et al.  Clinical features of amiodarone-induced pulmonary toxicity. , 1990, Circulation.

[12]  K. Ishak,et al.  Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients , 1989, Hepatology.

[13]  W. M. Smith,et al.  Long-term tolerance of amiodarone treatment for cardiac arrhythmias. , 1986, The American journal of cardiology.

[14]  J. Alpert,et al.  Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. , 1983, American heart journal.

[15]  K. Harjai,et al.  Effects of Amiodarone on Thyroid Function , 1997, Annals of Internal Medicine.

[16]  C. Wyndham,et al.  Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. , 1988, Journal of the American College of Cardiology.

[17]  F. Bogazzi,et al.  Amiodarone and the Thyroid , 1986 .